Immunological herpes simplex virus antigens and methods for use thereof
The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
1. A pharmaceutical composition comprising an isolated herpes simplex virus (HSV) polypeptide, wherein the HSV polypeptide comprises a U L 21 protein, and a pharmaceutically acceptable carrier.
2. A pharmaceutical composition comprising an isolated HSV polypeptide or a polynucleotide encoding same, and a pharmaceutically acceptable carrier, wherein the HSV polypeptide consists of an amount of a fragment of U L 21 effective to elicit activation of T cells, and wherein the fragment comprises amino acids 148-181 of U L 21.
3. A pharmaceutical composition comprising an isolated HSV polypeptide and a pharmaceutically acceptable carrier, wherein the HSV polypeptide consists of amino acids 148-181 of U L 21, and, optionally, a fusion partner.
4. The composition of claim 1 , wherein the polypeptide is a fusion protein comprising the isolated HSV polypeptide fused to an unrelated immunogenic protein.
5. The composition of claim 4 , wherein the fusion protein is soluble.
6. The composition of claim 2 , wherein the polypeptide is a fusion protein comprising the isolated HSV polypeptide fused to an unrelated immunogenic protein.
7. The composition of claim 6 , wherein the fusion protein is soluble.
8. A vector comprising a polynucleotide encoding an HSV polypeptide, wherein the HSV polypeptide consists of a fragment of U L 21 effective to elicit activation of T cells, and wherein the fragment comprises amino acids 148-181 of U L 21 of claim 2 .
9. A host cell transformed with the vector of claim 8 .
10. A method of producing an HSV polypeptide comprising culturing the host cell of claim 9 and recovering the polypeptide so produced.
11. An HSV polypeptide produced by the method of claim 10 .
12. A recombinant virus genetically modified to express the polypeptide of claim 11 .
13. The recombinant virus of claim 12 , which is a vaccinia virus, canary pox virus, lentivirus, retrovirus, herpes virus or adenovirus.
14. A pharmaceutical composition comprising the virus of claim 12 and a pharmaceutically acceptable carrier.
15. A recombinant non-HSV virus genetically modified to express the polypeptide of claim 11 .
16. The recombinant non-HSV virus of claim 15 , which is a vaccinia virus, canary pox virus, lentivirus, retrovirus, herpes virus or adenovirus.
17. A pharmaceutical composition comprising the non-HSV virus of claim 15 and a pharmaceutically acceptable carrier.
18. A fusion protein comprising an HSV polypeptide fused to a heterologous polypeptide, wherein the HSV polypeptide consists of amino acids 148-181 of U L 21.
19. A fusion protein of claim 18 that is soluble.
20. A polynucleotide that encodes a fusion protein of claim 18 .
21. A vector comprising the polynucleotide of claim 20 .
22. A host cell transformed with the vector of claim 21 .
23. A method of producing a fusion protein comprising culturing the host cell of claim 22 and recovering the fusion protein so produced.
24. A fusion protein produced by the method of claim 23 .
25. A fusion protein of claim 24 that is soluble.
26. A pharmaceutical composition comprising the fusion protein of claim 24 , and a pharmaceutically acceptable carrier.
27. A method of enhancing proliferation of HSV-specific T cells comprising contacting the HSV-specific T cells with an isolated polypeptide that comprises an immunogenic fragment of UL21, wherein the immunogenic fragment comprises amino acids 148-181 of UL21.
28. A method of enhancing the production of HSV-specific antibodies in a subject comprising administering to the subject the pharmaceutical composition of claim 2 .
29. A method of treating an HSV infection in a subject comprising administering the composition of claim 1 to the subject.
30. A method of treating an HSV infection in a subject comprising administering the composition of claim 2 to the subject.